A systematic review of 6 studies (2,267 patients) found contradictory evidence regarding whether continuing therapeutic warfarin increases complications after elective hip or knee arthroplasty.
Systematic Review (n=2,267)
Does continuation of therapeutic warfarin compared to prophylactic anticoagulation affect complication rates in patients undergoing elective hip or knee arthroplasty?
727 patients with therapeutic anticoagulation (1,540 controls) undergoing elective total hip arthroplasty (THA), total knee arthroplasty (TKA), and revision arthroplasty from 6 retrospective studies
Therapeutic anticoagulation with warfarin (including non-discontinuation)
Prophylactic dosages of one or more of the following: warfarin, aspirin, low-molecular-weight heparin (LMWH), and unfractionated low-dose heparin (UFH)
Complications including superficial wound infections, revision surgeries, postoperative haematomas, and prosthetic joint infections (PJI)safety
Perioperative management of chronic anticoagulation in elective arthroplasty remains controversial, with contradictory evidence regarding the safety of continuing therapeutic warfarin versus switching to prophylactic dosing.
INTRODUCTION: There are currently different management guidelines for patients undergoing elective total hip arthroplasty (THA) or total knee arthroplasty (TKA) that are on long-term anticoagulation. The timing of discontinuation and restarting the anticoagulation is challenging during the postoperative care, which often involves general practitioners and physiotherapists. METHODS: The systematic review followed the PRISMA guidelines and included 3 databases: PubMed/MEDLINE, EMBASE, and Web of Science Core Collection. It was registered in the International Prospective Register for Systematic Reviews and Meta-analysis (PROSPERO) under the registration number: CRD42023408906. The risk of bias assessment was performed using the Methodological index for non-randomized studies (MINORS) criteria. RESULTS: Six retrospective studies involving 727 patients with therapeutic anticoagulation (1,540 controls) for elective THA, TKA and revision arthroplasty have been included. The follow-up ranged from 30 days to 1 year postoperatively. All studies evaluated outcomes of warfarin therapeutic anticoagulation versus prophylactic dosages of one or more of the following: warfarin, aspirin, low-molecular-weight heparin (LMWH) and unfractionated low-dose heparin (UFH). One study did not discontinue therapeutic anticoagulation. Two studies reported no significant differences in complications between groups, whilst 3 studies had significantly higher rates of superficial wound infections, revision surgeries, postoperative haematomas, and prosthetic joint infections (PJI). CONCLUSION: Different anticoagulation-related perioperative management strategies achieve different outcomes following elective arthroplasty in patients with therapeutic chronic anticoagulation. There is contradictory evidence regarding the need for the discontinuation of therapeutic warfarin. Retrospective data showed that individual risk stratification with multi-modal prophylaxis resulted in minimal complications. LEVEL OF EVIDENCE: Systematic Review of Level III studies.
Building similarity graph...
Analyzing shared references across papers
Loading...
Diana Andronic
University of Health and Allied Sciences
Octavian Andronic
University of Zurich
Elias Ammann
University of Basel
Family Practice
Curtin University
Universitätsklinik Balgrist
University of Health and Allied Sciences
Building similarity graph...
Analyzing shared references across papers
Loading...
Andronic et al. (Fri,) conducted a systematic review in Elective total hip and knee arthroplasty on chronic anticoagulation (n=2,267). Therapeutic warfarin anticoagulation vs. Prophylactic dosages of warfarin, aspirin, LMWH, or UFH was evaluated on Complications including superficial wound infections, revision surgeries, postoperative haematomas, and prosthetic joint infections. A systematic review of 6 studies (2,267 patients) found contradictory evidence regarding whether continuing therapeutic warfarin increases complications after elective hip or knee arthroplasty.
synapsesocial.com/papers/6a0e4f1c285627488207874f — DOI: https://doi.org/10.1093/fampra/cmae020
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: